AFM
ITRM

Anson Funds Management’s Iterum Therapeutics ITRM Stock Holding History

Anson Funds Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-76,016
Closed -$447K – 392
2021
Q4 		$447K Buy
+76,016
New +$587K 0.04% 255

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Anson Funds Management's ITRM Position: Q1 2022 in Review

Anson Funds Management sold out of Iterum Therapeutics (ITRM) in Q1 2022, closing a stake of 76,016 shares — an estimated $447K sold.

Anson Funds Management first reported a position in ITRM in Q4 2021 and held it in 1 quarter. The position peaked at $447K in Q4 2021. 41 funds tracked by Wall St. Rank hold ITRM as of Q1 2022.

  • Anson Funds Management reported no remaining Iterum Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 76,016 Iterum Therapeutics shares in Q1 2022, an estimated $447K.
  • Anson Funds Management first reported a position in Iterum Therapeutics in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Iterum Therapeutics position peaked at $447K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.